Published in Cancer Immunol Immunother on November 12, 2011
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy. Neuro Oncol (2012) 2.04
The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS One (2015) 1.07
Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor. Mol Ther (2013) 1.04
Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother (2013) 0.89
Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis. J Cancer Res Clin Oncol (2013) 0.89
ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials. Cells (2012) 0.84
HSP70 promoter-driven activation of gene expression for immunotherapy using gold nanorods and near infrared light. Vaccines (Basel) (2014) 0.83
Allogeneic partially HLA-matched dendritic cells pulsed with autologous tumor cell lysate as a vaccine in metastatic renal cell cancer: a clinical phase I/II study. Hum Vaccin Immunother (2013) 0.80
Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. JCI Insight (2016) 0.78
Crucial Contributions by T Lymphocytes (Effector, Regulatory, and Checkpoint Inhibitor) and Cytokines (TH1, TH2, and TH17) to a Pathological Complete Response Induced by Neoadjuvant Chemotherapy in Women with Breast Cancer. J Immunol Res (2016) 0.75
Nomograms for Predicting the Prognostic Value of Pre-Therapeutic CA15-3 and CEA Serum Levels in TNBC Patients. PLoS One (2016) 0.75
Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses. Expert Rev Vaccines (2012) 0.75
Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol (2009) 1.40
Dendritic cells in the cancer microenvironment. J Cancer (2012) 1.40
New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Rev Vaccines (2010) 1.18
Evaluating the cytotoxicity of innate immune effector cells using the GrB ELISPOT assay. J Transl Med (2004) 1.15
Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin Cancer Res (2007) 1.12
Direct effects of carbon nanotubes on dendritic cells induce immune suppression upon pulmonary exposure. ACS Nano (2011) 1.11
Tumor associated regulatory dendritic cells. Semin Cancer Biol (2012) 1.08
Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine (2007) 1.07
Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J Immunol (2004) 1.07
Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. J Transl Med (2009) 1.03
Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunol Immunother (2011) 1.03
Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cell Oncol (Dordr) (2011) 1.01
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets. J Transl Med (2004) 1.01
Small rho GTPases regulate antigen presentation in dendritic cells. J Immunol (2005) 1.00
Antitumor effect of paclitaxel is mediated by inhibition of myeloid-derived suppressor cells and chronic inflammation in the spontaneous melanoma model. J Immunol (2013) 1.00
Cyanidin-3-rutinoside, a natural polyphenol antioxidant, selectively kills leukemic cells by induction of oxidative stress. J Biol Chem (2007) 0.98
Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner. J Immunotoxicol (2012) 0.98
Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT-PCR assays. J Neurosci Methods (2008) 0.96
Epigenetic mechanisms of promigratory chemokine CXCL14 regulation in human prostate cancer cells. Cancer Res (2010) 0.93
Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. J Immunotoxicol (2012) 0.93
Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells. J Immunother (2008) 0.92
Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood (2004) 0.91
Restoration by IL-15 of MHC class I antigen-processing machinery in human dendritic cells inhibited by tumor-derived gangliosides. J Immunol (2005) 0.90
Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. J Leukoc Biol (2002) 0.90
Carbon nanotubes enhance metastatic growth of lung carcinoma via up-regulation of myeloid-derived suppressor cells. Small (2012) 0.89
Biodiesel versus diesel exposure: enhanced pulmonary inflammation, oxidative stress, and differential morphological changes in the mouse lung. Toxicol Appl Pharmacol (2013) 0.89
Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunol Immunother (2013) 0.89
Application of a flow cytometric cytotoxicity assay for monitoring cancer vaccine trials. J Immunother (2009) 0.88
Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. J Exp Ther Oncol (2002) 0.88
Nano-gold corking and enzymatic uncorking of carbon nanotube cups. J Am Chem Soc (2015) 0.87
Graphene oxide, but not fullerenes, targets immunoproteasomes and suppresses antigen presentation by dendritic cells. Small (2012) 0.85
Inhibition of dendritic cell generation and function by serum from prostate cancer patients: correlation with serum-free PSA. Adv Exp Med Biol (2007) 0.85
Dual acute proinflammatory and antifibrotic pulmonary effects of short palate, lung, and nasal epithelium clone-1 after exposure to carbon nanotubes. Am J Respir Cell Mol Biol (2013) 0.84
Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunol Res (2011) 0.84
Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate (2004) 0.83
Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J Gene Med (2006) 0.82
Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Exp Gerontol (2004) 0.82
Optimizing dendritic cell-based immunotherapy for cancer. Expert Rev Vaccines (2007) 0.82
The role of TLR4 in the paclitaxel effects on neuronal growth in vitro. PLoS One (2013) 0.81
Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunol Immunother (2008) 0.81
Immunosuppressive mechanisms of regulatory dendritic cells in cancer. Cancer Microenviron (2013) 0.81
NK cells mediate Flt3 ligand-induced protection of dendritic cell precursors in vivo from the inhibition by prostate carcinoma in the murine bone marrow metastasis model. J Immunother (2003) 0.81
Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. J Urol (2003) 0.80
Dual role of immunomodulation by anticancer chemotherapy. Nat Med (2013) 0.80
Origin and pharmacological modulation of tumor-associated regulatory dendritic cells. Int J Cancer (2014) 0.80
Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. J Neuroimmunol (2003) 0.79
Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy (2011) 0.79
Small rho GTPases mediate tumor-induced inhibition of endocytic activity of dendritic cells. J Immunol (2007) 0.79
Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis. J Gene Med (2004) 0.78
Differentiation of immunostimulatory stem-cell- and monocyte-derived dendritic cells involves maturation of intracellular compartments responsible for antigen presentation and secretion. Stem Cells (2002) 0.78
Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications. Nanoscale (2015) 0.76
Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): moving forward. J Immunotoxicol (2012) 0.76
Differences in dendritic cell activation and distribution after intravenous, intraperitoneal, and subcutaneous injection of lymphoma cells in mice. Adv Exp Med Biol (2007) 0.76
Abnormalities in the male reproductive system after exposure to diesel and biodiesel blend. Environ Mol Mutagen (2014) 0.76
MicroRNAs are invading the tumor microenvironment: Fibroblast microRNAs regulate tumor cell motility and invasiveness. Cell Cycle (2010) 0.75
Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenviron (2013) 0.75
Cancer immunotherapy and immunomonitoring (CITIM): redefining cancer therapy. J Immunotoxicol (2009) 0.75
From cell regulation to patient survival: 2nd Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, Budapest, 2-5 May 2011. Cancer Immunol Immunother (2011) 0.75
Cancer and infection: friends or foes? Future Oncol (2012) 0.75